1. Introduction {#sec1-cancers-11-01730}
===============

The germline *TP53* R337H mutation is associated with a cluster of pediatric adrenocortical carcinoma (ACC) that is reported in Southern \[[@B1-cancers-11-01730]\] and Southeastern Brazil \[[@B2-cancers-11-01730]\], and accounts for the highest global incidence of childhood ACC \[[@B3-cancers-11-01730],[@B4-cancers-11-01730]\]. The most frequent clinical features of childhood ACC typically include virilizing syndrome (VS) with accelerated development of pubic hair, facial acne, phallus growth, voice change, facial hair, hirsutism, and muscle hypertrophy or growth acceleration in 84% of the reported cases. Approximately 29% of patients present cortisol overproduction, sometimes with signs and symptoms of Cushing´s syndrome (CS) \[[@B5-cancers-11-01730]\]. In contrast, features of adult ACC include secretory syndromes (60%) that are either a mixture of CS and VS (35%), CS (30%), or VS (20%) alone, feminizing syndrome (10%), and aldosterone-secreting carcinomas (2%) \[[@B6-cancers-11-01730]\]. Older children (without a clear cut-off age) commonly exhibit features observed more often in adult ACC patients than in young children, which is consistent with the hypothesis that the ACC phenotype found in very young children is probably embryonic in origin \[[@B7-cancers-11-01730],[@B8-cancers-11-01730],[@B9-cancers-11-01730]\].

Since the 1990s, global cooperative groups, particularly through the International Pediatric Adrenocortical Tumors Registry (IPACTR) and the Children's Oncology Group (COG) \[[@B10-cancers-11-01730]\], proposed improved treatment approaches for pediatric ACC. The current treatment for pediatric ACC is the combination of mitotane, cisplatin, etoposide, and doxorubicin, previously tested for adult ACC \[[@B11-cancers-11-01730]\], adapted by COG \[[@B10-cancers-11-01730]\], and put into use by Pediatric Oncology Centers \[[@B12-cancers-11-01730]\]. In the absence of other efficacious regimens, the COG protocol also focused on improving surgical procedures and minimizing chemotherapy and mitotane toxicities, with the aim to increase cure rates for stage 3 and 4 patients. However, this trial was compromised by an unexpected negative outcome of retroperitoneal lymph node dissection (RPLND) in stage 2 patients. This outcome provided insights into response adaptation and growth of the remaining circulating ACC cells after surgical trauma \[[@B13-cancers-11-01730]\]. Facilitated growth of these circulating ACC cells could be driven by inflammatory factors and/or diminished antitumor immune response.

Knowledge of malignant transformation of the childhood adrenal cortex has advanced significantly \[[@B14-cancers-11-01730],[@B15-cancers-11-01730]\], but reliable prognostic biomarkers that can distinguish early- and advanced-stage ACC remain scarce, and clinical versus pathological findings are often inconsistent \[[@B5-cancers-11-01730]\]. ACC in children under 5 years of age has more benign symptoms compared to older children with the same histopathological characteristics \[[@B16-cancers-11-01730],[@B17-cancers-11-01730],[@B18-cancers-11-01730]\]. Elevated expression of the Ki-67 proliferation marker has been associated with poor prognosis in both adults \[[@B19-cancers-11-01730],[@B20-cancers-11-01730],[@B21-cancers-11-01730]\] and older children \[[@B22-cancers-11-01730]\]. However, this association between Ki-67 expression and poor prognosis in pediatric ACC is not consistent \[[@B17-cancers-11-01730]\]. In contrast, other authors did not recommend Ki-67 immunohistochemistry in clinical practice to differentiate benign from malignant adrenocortical tumors without establishing a cut-off value for Ki-67 expression \[[@B23-cancers-11-01730],[@B24-cancers-11-01730]\]. Furthermore, to increase the power of the prognostic value of Ki-67 in adult ACC, the Helsinki Score was proposed and validated as a measurement of mitosis, necrosis, and Ki-67 immunostaining \[[@B25-cancers-11-01730],[@B26-cancers-11-01730]\]. Other prognostic modifiers should probably be considered. For example, hypercortisolism without virilization is usually associated with worse prognosis \[[@B5-cancers-11-01730],[@B27-cancers-11-01730]\].

The role played by the immune system in human cancers has been extensively studied. Elevated exogenous or endogenous corticosteroid levels may downregulate the immune system \[[@B28-cancers-11-01730],[@B29-cancers-11-01730]\]. The expression of HLA class I and II molecules in antigen presenting cells (APC) in tumors are key steps in the presentation of tumor antigens to T-lymphocytes (cytotoxic T lymphocytes; CTL) to generate an effective antitumor immune response \[[@B30-cancers-11-01730],[@B31-cancers-11-01730],[@B32-cancers-11-01730]\]. CTL are cluster of differentiation 8 positive (CD8^+^), whereas T-helper and T-regulatory cells (Treg) are cluster of differentiation 4 positive (CD4^+^). CD8 is a transmembrane glycoprotein co-receptor of T-cell receptor (TCR) \[[@B33-cancers-11-01730]\]. Mature CTLs (activated CD8^+^ T cells) are required to eliminate tumor cells, but impairment in cancer immunity may inhibit receptor signaling and lead to tumors that can evade the immune system \[[@B32-cancers-11-01730]\]. Cancer cells regularly harness CTL antigen 4 (CTLA-4 or CD152) and programmed cell death-1 (PD-1 or CD279) immune-checking molecules to escape detection and elimination by the immune system \[[@B34-cancers-11-01730],[@B35-cancers-11-01730],[@B36-cancers-11-01730],[@B37-cancers-11-01730]\]. This escape is usually mediated by elevated binding of the PD-L1 antigen in tumors to PD-1 receptors in CTL \[[@B34-cancers-11-01730]\]. The PD-1 receptor and its ligand PD-L1 are an important part of the immune checkpoint mechanism and are important mediators of tumor-induced immune suppression that have emerged as important biomarkers for screening cancers amenable to immunotherapy. It is believed that most PD-L1-expressing tumors may respond to PD-1/PD-L1 inhibitors \[[@B32-cancers-11-01730],[@B37-cancers-11-01730]\]. Indeed, there is some evidence that PD-L2 is associated with decreased survival and decreased CD8^+^ tumor-infiltrating lymphocytes in patients with esophageal cancer and could be a viable treatment target for many cancers, because it has a greater affinity for the PD-1 receptor than PD-L1 \[[@B38-cancers-11-01730],[@B39-cancers-11-01730]\]. Studies regarding PD-1 and PD-L1 expression in ACC patients are limited; Fay et al. \[[@B40-cancers-11-01730]\] reported that 10% PD-L1 expression in ACC cell membrane had no relationship with clinico-pathologic parameters or survival. Conversely, Tierney et al. \[[@B41-cancers-11-01730]\] reported that PD-L1-positive cells accounted for only 2.9% (1/34) of ACC, contrasting with 44% (15/34) for PD-L2. These findings are consistent with the modest results from a multicenter phase IB trial that used antibody targeting PD-L1 \[[@B42-cancers-11-01730]\].

Some solid tumors are known to be infiltrated by CD8^+^ cells, suggesting that these tumors are able to attract these cells through the presentation of specific antigens \[[@B43-cancers-11-01730]\]. These antigens are bound by class I major histocompatibility complex (MHC) molecules, which help activate CTL and kill cancer cells \[[@B44-cancers-11-01730],[@B45-cancers-11-01730]\]. Thus, the degree of CD8^+^ CTL infiltrated in solid tumors was found to be inversely correlated with tumor size, staging, and poor prognosis in colorectal cancer \[[@B46-cancers-11-01730]\], prostate cancer \[[@B47-cancers-11-01730]\], stomach cancer \[[@B48-cancers-11-01730],[@B49-cancers-11-01730]\], melanoma \[[@B50-cancers-11-01730],[@B51-cancers-11-01730]\], lung cancer \[[@B52-cancers-11-01730]\], ovarian cancer \[[@B53-cancers-11-01730]\], endometrial carcinoma \[[@B51-cancers-11-01730],[@B54-cancers-11-01730]\], and other tumor types.

The present study was designed to evaluate Ki-67, CD8^+^ CTL, PD-1, and PD-L1 expression in ACC of young children by immunohistochemistry (IHC). The main goal was to assess whether their expression is associated with age at diagnosis, disease free survival (DFS), and outcome.

2. Results {#sec2-cancers-11-01730}
==========

Demographic, clinical, and histopathological data from a cohort of 48 children with ACC are summarized in [Table 1](#cancers-11-01730-t001){ref-type="table"}. All deceased patients ultimately died of disease within the first 4 years after diagnosis because of disease progression and/or relapses. The patient cohort included 30 girls and 18 boys, ranging from 5 d to 9.75 y of age with a mean age at diagnosis of 2.83 ± 2.3 y (mean ± SD), which presented virilization (40/48, 83%), CS (11/48, 23%), and hypertension (4/48, 8%). All stage 3 patients described in [Table 1](#cancers-11-01730-t001){ref-type="table"} were diagnosed either with vena cava invasion (*N* = 2), or had local invasion associated with contiguous invasion to the kidney with rupture of the tumor (*N* = 2). Stage assessment and treatment were performed according to the COG protocol \[[@B10-cancers-11-01730]\] except for stage 2 RPLND, which was not performed in the present study. Adrenocortical adenoma (ACA), ACC with undetermined histology, deaths unrelated to ACC, or living patients with less than 3 y DFS after the last operation were excluded from the present study. Postoperative therapy was similar between all patients and according to the COG guidelines \[[@B10-cancers-11-01730]\]. The minimum follow-up time for all patients free of disease was 3 y.

Advanced stage and age at ACC diagnosis ≥3 years were significantly associated with lower survival rates ([Figure 1](#cancers-11-01730-f001){ref-type="fig"}). Conversely, ACC with a Weiss score = 3 was not significantly associated with a higher DFS in comparison with cases with score 4 or higher.

2.1. Histology and Immunostaining of ACC Tumors {#sec2dot1-cancers-11-01730}
-----------------------------------------------

### Ki-67, CD8 and PD-1/PD-L1 as markers for ACC prognosis

Evaluation of nuclear staining for Ki-67 in ACC cells was carried out by two independent observers (Thiago D. Woiski and Lúcia Noronha). We used previously reported counting methods for Ki-67 \[[@B21-cancers-11-01730]\] and CD8 \[[@B46-cancers-11-01730],[@B55-cancers-11-01730]\]. For each sample, ten high-power fields (HPF = 400×) with the most abundant distribution were selected and manually counted. Each tumor was scored at three mean cutoff levels (\< or ≥10%, 15%, or 20% of 100 tumor cells) for the Ki-67 labeling index (LI), whereas mean absolute number of CD8 immunopositive cells in ten high-power fields (HPF = 400×) was expressed at three cutoff levels (\< or ≥10, 15, or 20 cells per HPF). The relationship between either Ki-67 LI or CD8^+^ -CTL counts per HPF and overall survival was evaluated using Kaplan-Meier DFS analysis ([Figure 2](#cancers-11-01730-f002){ref-type="fig"}). We found significant prognostic values for two cutoffs of CD8^+^-CTL counts (15 and 20) but not for Ki-67 LI. Ki-67 also failed to reach significance in univariate ([Table S1](#app1-cancers-11-01730){ref-type="app"}) and multivariate Cox analyses of stage as well as for ages above and below 3 y ([Table 2](#cancers-11-01730-t002){ref-type="table"}).

Two different distribution patterns for CD8^+^-CTL were identified and termed nodular and diffuse. The multifocal distribution pattern was associated with higher counts of CD8^+^-CTL. In contrast, there was a diffuse pattern of CD8^+^-CTL associated with its lower counts ([Figure 3](#cancers-11-01730-f003){ref-type="fig"}).

A single immunostaining pattern was observed for Ki-67-positive nuclei, which presented a wide range of counts between 1% and 70% ([Figure 4](#cancers-11-01730-f004){ref-type="fig"}).

Given the significant DFS difference between early stages (1 + 2) and advanced ACC (*p* \< 0.00001; [Figure 1](#cancers-11-01730-f001){ref-type="fig"}), and the low number of ACC cases, additional analyses were performed to evaluate the prognostic value for Ki-67 LI and CD8^+^ positive CTL between two extreme prognostic groups. Group A included patients in stage 1 and 2 that were living disease-free for at least 3 y, and Group B was composed of all stage 3 and 4 patients that were alive or deceased, plus all stage 1 or 2 patients who died of disease. These two groups were compared using the Fisher's Exact Test ([Table 3](#cancers-11-01730-t003){ref-type="table"}) and analyses showed striking differences in CD8^+^-CTL counts and age of ACC diagnosis. In contrast, none of the Ki-67 LI values were statistically different between groups A and B.

Similarly, in a multivariate Cox analysis for advanced staging and age ≥3 y, or combining low CD8^+^-CTL counts and age ≥3 y, we were able to predict a significant correlation ([Table 2](#cancers-11-01730-t002){ref-type="table"}).

Positivity in IC cells is usually graded into none, 1--5%, 5--10%, and \>10%. The percentage was calculated as a percentage of immune cells that were positive (including lymphocytes and macrophages) from the total of immune cells. PD-L1-positive cells (\<5%) were found in only four of the 19 tested ACC samples (21%), all of them exclusively in the tumor-associated immune cell component. PD-1-positive staining was not detected in immunoreactive tumor cells of any patient, only in positive controls ([Figure 5](#cancers-11-01730-f005){ref-type="fig"}).

Individual semiquantitative PD-1/PD-L1 results are presented in [Table 4](#cancers-11-01730-t004){ref-type="table"}. The overall mean age of the children was 2.74 ± 2.4 y (mean ± SD). These findings suggest that the PD-1/PD-L1 pathway does not play a major role in ACC, and, given the modest results obtained for PD-1 and PD-L1, no further tests were performed to correlate those data to ACC prognosis.

3. Discussion {#sec3-cancers-11-01730}
=============

ACC assessment and treatment have evolved thanks to COG and other international consortia, but currently additional value is being placed on finding new prognostic biomarkers to predict outcome. To critically evaluate the markers in the present study, we considered different statistical models to evaluate prognosis and overall patient survival. We excluded adrenocortical adenomas (ACAs), undetermined adrenocortical tumors, deaths unrelated to ACC, wild-type germline *TP53*, and all cases of living patients with an uncertain outcome (\<3 y of follow-up without recurrence or free of disease). Ki-67 expression in tumor cells was transformed into a categorical variable (\< or ≥10%, 15%, or 20%), but failed to predict prognosis of young children with ACC carrying the *TP53 R337H* germline mutation. Kaplan-Meier/Log rank and univariate/multivariate Cox hazard analysis also did not support a predictive prognostic value for Ki-67 LI. Ki-67 expression also failed to differentiate stage 1 in living and disease-free patients from those with advanced tumors. Several attempts have been made to evaluate the prognostic significance of Ki-67 expression, and there is a consensus that Ki-67 is a reliable prognostic factor for adult ACC. A comparison among carcinoma groups was systematically performed according to European Network for the Study of Adrenal Tumors (ENSAT) staging \[[@B20-cancers-11-01730],[@B21-cancers-11-01730],[@B23-cancers-11-01730],[@B25-cancers-11-01730],[@B27-cancers-11-01730],[@B56-cancers-11-01730]\]. However, the Ki-67 LI was not consistently associated with overall survival in stage 3 and 4 ACC \[[@B23-cancers-11-01730]\].

Our patients are predominantly very young, with a mean age of 2.83 ± 2.3 y (± SD), who had typical clinical features represented by the predominance of virilization (83%) over CS (23%) and virilization combined with hypertension (8%). Children from the International Registry (IPACTR) who were over 13 y had a significantly lower survival rate than children under 3 y \[[@B5-cancers-11-01730]\]. Interestingly, a pediatric ACC series from IPACTR with important differences in relation to our study (e.g., higher mean age, higher frequency of Cushing signs, lower frequency of virilization, absence of *TP53* germline mutations, inclusion of adenomas, and differences in disease-free survival) reported a significant association between high Ki-67 expression and worse prognosis \[[@B22-cancers-11-01730]\]. However, these features are more similar to the adult ACC phenotype and the authors included adenomas and follow-up less than three years after treatment initiation, and did not describe the proportion of cases defined as stage 3 without vena cava invasion. These important methodological differences may affect the relevance of the Ki-67 LI associated with prognosis, and further studies with less heterogenous parameters are necessary to accurately evaluate Ki-67 LI use as a consistent disease marker.

Given the overall absence of PD-1 and PD-L1 immunoreactive tumor cells and 4/19 ACC tumor samples expressing PD-L1 (\<5% (1+) in immune cells, it is less likely that the PD-1/PD-L1 immune escape pathway plays an important role in pediatric ACC. Similarly, only three (10.7%) PD-L1-positive cases were found in tumor samples among 28 adult ACCs \[[@B40-cancers-11-01730]\]. Tierney et al. \[[@B41-cancers-11-01730]\] found the low PD-L1 and strong PD-L2 expression in ACC tumors and stromal tissues than in ACAs, suggesting that PD-L2 could be a target for immunotherapy. Collectively, only a small number of patients could benefit from therapy using PD-1/PD-L1 inhibitors, which was recently demonstrated in a clinical trial \[[@B42-cancers-11-01730]\].

ACC was reported as being a tumor type with the lowest immunologic response \[[@B57-cancers-11-01730]\], which raises several questions about the feasibility of immunotherapy or therapeutic vaccine development against ACC. Fewer tumor infiltrating CD8^+^ T lymphocytes were reported to be associated with lower *HLA*-*DPA1* and *HLA*-*DPB1* expression in several pathologies \[[@B58-cancers-11-01730]\], supporting the hypothesis that the loss of tumor immunosurveillance can have a devastating effect on tumor antigen presentation, loss of mature CTL, and patient outcome. Association between infiltrated CD8^+^ cells and a better ACC prognosis was also found in a multivariate Cox regression analysis for staging and patient age. Interestingly, *HLA*-*DPA1* is predominantly expressed in hematopoietic infiltrating cells in adrenocortical adenomas \[[@B37-cancers-11-01730]\]. We observed that the multifocal (agglomerate) pattern of CD8^+^ cell infiltration predominates the diffuse distribution observed in ACC. The CD8^+^ focal pattern is more similar to the patterns reported in lung, breast, and colorectal cancers and melanoma than the diffuse pattern described in prostate or gastric cancers \[[@B59-cancers-11-01730]\]. The multifocal pattern of CD8^+^ T lymphocyte distribution pattern in ACC could be influenced by the density of branching vessels (arborescent), with activated CD8^+^-cytotoxic T lymphocytes coming from the lymph nodes where antigen presenting cells may interact and activate immature cytotoxic T lymphocytes \[[@B32-cancers-11-01730]\]. This pattern varies among tumors; for example in breast cancer, most of the tumor infiltrating CD8^+^ T lymphocytes are detected at the host--tumor interface than in the intra-tumor stroma \[[@B59-cancers-11-01730]\].

4. Methods {#sec4-cancers-11-01730}
==========

4.1. Subjects and Samples {#sec4dot1-cancers-11-01730}
-------------------------

ACC tumor samples from 48 children were processed for immunohistochemistry (IHC). All ACC patients, three control children without cancer, and half of the parents were carriers of the germline *TP53* R337H mutation. Written informed consent was provided by the patients' guardians. This study was approved by the Pequeno Príncipe Hospital Ethics Committee (Curitiba, Paraná state, Brazil, under ethic codes CAA: 0023.0.208.000-05 (2005), CAAE 0612.0.015.000-08 (2009 and 2012) and by the Hospital Joana Gusmão (Florianópolis, Santa Catarina state, Brazil, under ethic codes HIJG-006/2015, HIJG-003/2016, HiJG-006/2017) Ethics Committees for the IHC studies.

4.2. Immunohistochemistry {#sec4dot2-cancers-11-01730}
-------------------------

Only primary adrenocortical carcinomas (ACC) carrying the germline *TP53* R337H mutation were included in IHC analysis. After deparaffinization and rehydration of 4-μm thick sections, endogenous peroxidase was inactivated with 0.5% Hydrogen Peroxide Block buffer (Sigma, Cambridge, MA, USA) for 10 min at room temperature. Antigen recovery was carried out by leaving the samples in Immuno Retriever buffer (Thermo Fisher™, Waltham, MA, USA) in a bath at 99 °C for 25 min. After cooling and washing, samples were incubated with primary antibodies overnight at 4 °C in a moist chamber. Tumor infiltrating T-cells and the Ki-67 labeling index were evaluated by IHC using the REVEAL-Polyvalent HRP Kit (Spring Bioscience, Pleasanton, CA, USA). The following primary antibodies were used: anti-CD8 (monoclonal rabbit, dilution 1:200, Thermo Fisher™) and anti-Ki-67 (monoclonal rabbit, dilution 1:200, Cell Marque™, Rocklin, CA, USA). All staining procedures included positive (e.g., tonsil) and negative controls (e.g., no primary antibody). The slides were then washed and incubated in Spring REVEAL complement buffer for 10 min at room temperature. Afterwards, the slides were washed and incubated with Spring REVEAL Conjugate for 15 min at room temperature. The slides were washed and revealed with DAB Chromogen (Thermo Fisher Scientific, Fremont, CA, USA) (1:1) and counterstained with Harris hematoxylin (Sigma-Aldrich, St. Louis, MO, USA).

The anti-CD8 and anti-Ki-67 immunostained slides were observed using a Zeiss^®^ AXIO SCOPE.A1 light microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). For each sample, ten high-power fields (HPF = 400×) with the most abundant distribution were selected and manually counted. For Ki-67, the number of positive cells were counted for 100 cells per HPF and the percentage was used for statistical calculations as suggested \[[@B20-cancers-11-01730]\]. Assessment of CD8^+^ T lymphocytes included counting the number of CD8^+^ membrane-stained tumor infiltrating lymphocytes in each HPF of the sample. The average was used for statistical calculations \[[@B46-cancers-11-01730],[@B55-cancers-11-01730]\].

IHC for PD-L1 was performed in 18 ACC samples with the *TP53* R337H mutation according to a previous study \[[@B60-cancers-11-01730]\]. Briefly, two commercially available antibodies for anti-PD-L1: antibody CAL10 (Biocare Medical, Pacheco, CA, USA) and the IVD versions of the PD-L1 IHC 22C3 pharmDx (DAKO Agilent Technologies, Santa Clara, CA, USA) were analyzed with the DAKO Autostainer Link 48 (Agilent Technologies, Santa Clara, CA, USA) and Ventana BanchMark (Ventana Medical System, Tucson, AZ, USA) platforms, respectively. Neoplastic cells were considered positive when any cell membrane staining (partial or complete) was present, and pure cytoplasmic immunoreactions were ignored.

IHC for PD-1 was performed as previously described \[[@B61-cancers-11-01730]\] using the primary antibody EPR4877 (Abcam) at room temperature. Sections were further incubated with peroxidase-labeled secondary antibody for 30 min at room temperature. For antigen visualization, sections were immersed in 3-amino-9-ethylcarbazole plus substrate-chromogen for 30 min and counterstained with Gill's hematoxylin.

The immunostained slides were observed on a Zeiss^®^ AXIO SCOPE.A1 optical microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). For each sample, ten high-power fields (400×) were randomly selected and the average of the percentage of immunopositive cells was used for statistical calculations.

4.3. Statistical Analysis {#sec4dot3-cancers-11-01730}
-------------------------

We used R statistical software, version 3.5.0 R Core Team, 2018 \[[@B62-cancers-11-01730]\] for all analyses. Survival curves were calculated according to the Kaplan-Meier method. The log-rank test was applied to detect significant survival differences between groups. The Kaplan-Meier non-parametric estimator was used to estimate the survival function of ACC patients for each of the covariates: staging, age group, Ki-67 LI percentages, CD8 counts (low or high), and a Weiss score ≥3 \[[@B63-cancers-11-01730]\]. Univariable and multivariable Cox proportional hazard regression analysis was performed to identify the hazard ratios (HR) between pathological and clinical variables (staging, age group, Ki-67 group and CD8 group). The descriptive analysis was performed to verify the minimal quantities and percentages for the categorical variables (i.e. outcome, staging, age group, CD8 counts, and Ki-67 LI levels). Chi-square and Fisher's exact tests were used to compare the dependency ratio between two categorical variables. The overall survival time was considered to be the elapsed time from the diagnosis until death or censorship (variable "time of follow-up").

5. Conclusions {#sec5-cancers-11-01730}
==============

Relative risk prediction for childhood ACC beyond the classical clinical and histopathological parameters clearly depends on a number of parameters, including the status of the immune system, age at diagnosis, presence or absence of corticoid-mediated inhibition of the immune system, non-MHC genetic or epigenetic variants, and chromosome instability associated with p53 dysfunction, among others. The emerging evidence suggests that a better understanding of the CD8^+^ cytotoxic T lymphocytes could reveal variants in antigen presenting cells. However, restricted analysis to CD8^+^ cytotoxic T lymphocytes could lead to unexpected conclusions about ACC prognosis and outcome. Further studies and functional analyses are necessary to estimate HLA variants, the genotype versus phenotype of malignancy to identify the mechanisms of immune response in ACC. In addition, treatment should include attempts to modulate or improve immune response \[[@B64-cancers-11-01730]\] at the primary tumor site because the overall survival for metastatic ACC is challenging and disappointing. These options may include enhancement of targets for CD8^+^ T cell recognition, as described for other human cancers \[[@B32-cancers-11-01730],[@B65-cancers-11-01730],[@B66-cancers-11-01730]\] in combination with mitotane, cisplatin, etoposide, doxorubicin (EDPM), and/or targeted therapies.
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The following are available online at <https://www.mdpi.com/2072-6694/11/11/1730/s1>, Table S1: Univariate Cox analysis of staging group, age group, Ki-67 LI, and CD8^+^-CTL counts.
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![Kaplan-Meier analyses of staging, age at diagnosis, and Weiss score on disease free survival. All death cases were related to the disease. Surviving patients had more than 3 years without recurrence.](cancers-11-01730-g001){#cancers-11-01730-f001}

![Kaplan-Meier analyses of overall survival for cluster of differentiation 8 (CD8) (cells/high power field (HPF)) and Ki-67 (% cells in HPF) indices at three cutoff levels. For each sample, ten high-power fields (HPF = 400×) with the most abundant ki-67 and CD8 distributions were selected and manually counted.](cancers-11-01730-g002){#cancers-11-01730-f002}

![Immunohistochemistry of CD8 in adrenocortical carcinoma (ACC). (**A** and **D**) Low magnification (20×) images of hematoxylin and eosin stain (HE) of ACC. Diffuse, low CD8 immunostaining (**B**, 20×; **C**, 40×). Nodular CD8 immunostaining (**E**, 20×; **F**, 40×). Scale bar: A, D, B, and E = 100 µm; C and F = 50 µm.](cancers-11-01730-g003){#cancers-11-01730-f003}

![Ki-67 immunohistochemistry in ACC. Low magnification (20×) images shown in **A** and **D** depict HE staining of ACC. Low Ki-67 immunostaining is shown in **B** (20×) and **C** (40×). High Ki-67 expression is shown in **E** (20×) and **F** (40×). Scale bar: A, D, B, and E = 100 µm; C and F = 50 µm.](cancers-11-01730-g004){#cancers-11-01730-f004}

![**Programmed death 1** (PD-1)/Programmed death-ligand 1 (PD-L1) staining profile in ACC and positive controls (+ ctrl). IC: immune cells. Scale bars: a, b, d: 50 µm; c: 100 µm.](cancers-11-01730-g005){#cancers-11-01730-f005}

cancers-11-01730-t001_Table 1

###### 

Clinical and adrenocortical carcinomas (ACC) histological features.

  Code   Gender   Age at Diagnosis   Clinical Manif.   Staging   Surgical Ressection   CT/M \*\*   Recurrence   DFS     Outcome   Weight (g)   Weiss   CD8 Counts (Cells/HPF)   Ki-67 LI
  ------ -------- ------------------ ----------------- --------- --------------------- ----------- ------------ ------- --------- ------------ ------- ------------------------ ----------
  1      F        1y10m              V                 1         Total                 No          No           3y1m    Well      77           8       17,8                     10
  2      F        1y6m               V                 2         Total                 No          No           8y7m    Well      127          5       22,7                     7
  3      F        3y4m               V                 3         Total                 CT/M        Yes          5m      DD        125          9       1,2                      50
  4      F        8y                 V                 3         Total                 CT/M        No           10y3m   Well      300          3       22                       14
  5      M        2y4m               V+C               4         Total                 CT/M        No           12y6m   Well      80           5       8,8                      14
  6      M        9m                 NF                2         Total                 M           No           6y      Well      300          6       18,2                     15
  7      F        8m                 V+C               1         Total                 No          No           3y      Well      62           7       3,2                      53
  8      F        2y4m               V                 2         Total                 M           No           3y3m    Well      275          5       4,2                      18
  9      M        1y1m               V                 1         Total                 No          No           6y9m    Well      12           5       37,8                     37
  10     F        1y9m               V+C               4         Total                 CT/M        Yes          1y1m    DD        392          8       48,2                     55
  11     F        11m                V+C               1         Total                 No          No           3y11m   Well      33           5       7,7                      22
  12     F        4y5m               V                 3         Partial               CT/M        Yes          1y6m    DD        440          4       12,3                     13
  13     F        1y2m               V+C               2         Total                 No          No           6y7m    Well      212.21       7       9,7                      18
  14     M        10m                V+C               2         Total                 No          No           3y      Well      105          4       1,6                      19
  15     M        2y11m              V                 2         Total                 M           No           12y4m   Well      300          5       52,9                     17
  16     M        1y                 ABM               2         Total                 No          No           3y4m    Well      126          5       25,6                     70
  17     M        7y2m               No                2         Total                 CT/M        No           4y10m   Well      238          6       24,9                     35
  18     F        4y5m               V                 2         Total                 CT/M        No           3y8m    Well      318          8       27,9                     56
  19     F        8m                 V                 1         Total                 No          No           3y      Well      16           4       24,6                     48
  20     F        6y8m               V                 4         Total                 CT/M        Yes          1y3m    DD        342          9       16                       70
  21     F        10m                V+C               2         Total                 No          No           11y1m   Well      135          3       3,2                      2
  22     F        1y8m               V+C               1         Total                 No          No           6y8m    Well      \*           \*      25,3                     11
  23     M        9y9m               V+C               1         Total                 CT/M        Yes          1y8m    DD        \*           \*      6                        7
  24     M        2y9m               V+H               4         Total                 CT/M        Yes          2y11m   DD        625          7       0,7                      15
  25     M        8y5m               No                1         Total                 CT/M        Yes          1y3m    DD        22           7       1,9                      22
  26     M        4y5m               V                 1         Total                 No          No           25y8m   Well      15           4       48,1                     4
  27     M        11m                ABM               2         Total                 No          \*           11y6m   Well      320          5       1                        3
  28     F        2y3m               V                 1         Total                 No          No           14y8m   Well      60           4       17,6                     1
  29     F        5y6m               V                 2         Total                 CT/M        Yes          3y10m   DD        690          8       1,9                      20
  30     F        5days              ABM               1         Total                 No          No           15y1m   Well      10           3       39,7                     10
  31     F        6m                 V                 4         Total                 CT/M        Yes          11/8m   Well      50           6       0,1                      12
  32     F        1y6m               V+H               1         Total                 No          No           11y     Well      20           \*      5,5                      4
  33     F        2y8m               V                 1         Total                 No          No           4y7m    Well      18           4       66,4                     8
  34     M        1y4m               V                 2         Total                 No          No           14y4m   Well      165          7       36,1                     25
  35     F        7y3m               V+H               4         Total                 CT/M        No           4m      DD        400          4       34,9                     10
  36     F        5y3m               V                 4         Total                 CT/M        Yes          1y1m    DD        250          7       2,3                      12
  37     F        1y11m              V                 1         Total                 No          No           8y3m    Well      18           3       14,7                     22
  38     F        4y2m               V                 4         Total                 CT/M        Yes          1y7m    DD        750          6       4                        12
  39     F        8m                 V                 1         Total                 No          No           5y8m    Well      100          6       4,4                      12
  40     F        2y7m               V                 1         Total                 No          No           21y     Well      20           \*      22                       \*
  41     F        7m                 V+C               1         Total                 M           Yes          15y3m   Well      100          \*      68                       \*
  42     M        2y7m               V                 1         Total                 No          \*           21y     Well      50           \*      43                       \*
  43     M        1y10m              V                 2         Total                 No          \*           4y9m    Well      170          \*      0                        \*
  44     F        1y3m               ABM               2         Total                 No          No           11y9m   Well      265          \*      76                       \*
  45     M        3y4m               V                 3         Total                 CT/M        Yes          2m      DD        370          \*      9                        \*
  46     M        3y2m               V+C               4         Partial               CT          Yes          1y8m    DD        \*           \*      0                        \*
  47     F        3y6m               ABM               4         Total                 CT/M        Yes          3y      DD        123          \*      0                        \*
  48     M        2y10m              V+H               4         Total                 CT/M        Yes          1y5m    DD        1050         \*      10                       \*

\* Not available; \*\* After total primary tumor resection, patients later developed metastases and were treated with CTM. DFS, Disease-free survival. F = female, M = male, V = virilization, C = Cushing, H = Hypertension, CT = chemotherapy, M = Mitotane, DD = died of disease; Y, yes, N, no; ABM, abdominal mass; Well means alive without signs of disease. CD8: cluster of differentiation 8, HPF: high power field, LI: labeling index.

cancers-11-01730-t002_Table 2

###### 

Multivariate Cox analysis of stage, age group, Ki-67 LI, and CD8^+^-cytotoxic T lymphocites (CTL) counts.

  Parameters            Coefficient   Hazard Ratio   Standard Error   z       *p* Value
  --------------------- ------------- -------------- ---------------- ------- -----------
  Stages 3 and 4        2.149         8.578          0.704            3.055   0.002
  Age ≥ 3 years         1.746         5.729          0.698            2.5     0.012
  Stages 3 and 4        2.658         14.26          0.86             3.091   0.002
  Age ≥ 3 years         1.914         6.78           0.818            2.34    0.019
  Ki-67 ≥ 20%           1.286         3.618          0.75             1.714   0.086
  Age ≥ 3 years         2.647         14.11          0.787            3.362   \<0.001
  Ki-67 ≥ 15%           0.223         1.25           0.609            0.367   0.714
  Age ≥ 3 years         2.635         13.94          0.798            3.303   \<0.001
  Ki-67 ≥ 20%           0.028         1.028          0.616            0.046   0.964
  Age ≥ 3 years         2.552         12.84          0.659            3.872   \<0.001
  CD8 \< 15 cells/HPF   1.377         3.963          0.657            2.096   0.036
  Age ≥ 3 years         2.661         14.31          0.665            4.005   \<0.001
  CD8 \< 20 cells/HPF   1.705         5.503          0.775            2.201   0.028

cancers-11-01730-t003_Table 3

###### 

Good (A) and worse (B) prognostic subgroups discriminated using different indices and parameters.

  -----------------------------------------------------------------------------------
  Parameters        Subroup A\           Subgroup B\                      *p*-Value
                    (Stages 1+2 Well)\   (All Stages DD and 3+4 Alive)\   
                    *n* (%)              *n* (%)                          
  ----------------- -------------------- -------------------------------- -----------
  **Staging**                                                             \<0.001

  1                 16 (88.9)            2 (11.1)                         

  2                 14 (93.3)            1 (6.7)                          

  3                 0 (0)                4 (100)                          

  4                 0 (0)                11 (100)                         

  **CD8^+^-CTL**                                                          0.052

  \<10              10 (45.5)            12 (54.5)                        

  ≥10               20 (76.9)            6 (23.1)                         

  \-                                                                      0.008

  \<15              11 (44)              14 (56)                          

  ≥15               19 (82.6)            4 (17.4)                         

  \-                                                                      0.016

  \<20              14 (48.3)            15 (51.7)                        

  ≥20               16 (84.2)            3 (15.8)                         

  **Ki-67**                                                               0.218

  \<10%             7 (87.5)             1 (12.5)                         

  ≥10%              18 (58.1)            13 (41.9)                        

  \-                                                                      0.65

  \<15%             11 (57.9)            8 (42.1)                         

  ≥15%              14 (70)              6 (30)                           

  \-                                                                      1

  \<20%             16 (64)              9 (36)                           

  ≥20%              9 (64.3)             5 (35.7)                         

  **Weiss_Score**                                                         1

  =3                3 (75)               1 (25)                           

  \>3               20 (62.5)            12 (37.5)                        

  **Age**                                                                 \<0.001

  ≥3 years          3 (18.8)             13 (81.2)                        

  \<3 years         27 (84.4)            5 (15.6)                         

  **Outcome**                                                             \<0.001

  DD                0 (0)                15 (100)                         

  Well              30 (90.9)            3 (9.1)                          
  -----------------------------------------------------------------------------------

DD means died of disease. CTL: cytotoxic T lymphocytes. The Chi-square and Fisher's exact tests were used to compare the differences between subgroups.

cancers-11-01730-t004_Table 4

###### 

ACC stage and Programmed death 1 (PD-1)/Programmed death-ligand 1 (PD-L1) immunostaining.

  Code   Age of Diagnosis   Clinical Manifestation   Stage   PD-L1 TC   PD-L1 IC    PD-1
  ------ ------------------ ------------------------ ------- ---------- ----------- ------
  1      1y10m              V                        1       0          \<5% (1+)   0
  2      1y6m               V                        1       0          0           0
  3      3y4m               V                        3       0          0           0
  4      8y                 V                        3       0          0           0
  5      2y4m               V+C                      4       0          0           0
  6      9m                 NF                       2       0          0           0
  7      8m                 V+C                      1       0          0           0
  8      2y4m               V                        2       0          0           0
  9      1y1m               V                        1       0          0           0
  10     1y9m               V+C                      4       0          0           0
  15     2y11m              V                        2       0          \<5% (1+)   0
  16     1y                 ABM                      2       0          \<5% (1+)   0
  17     7y2m               No                       2       0          \<5% (1+)   0
  19     8m                 V                        1       0          0           0
  20     6y8m               V                        4       0          0           0
  26     4y5m               V                        2       0          0           0
  a      4y5m               V                        3       0          0           0
  b      1m22days           No                       1       0          0           0
  c      11m                V                        2       0          0           0

V = virilization, C = Cushing, No = asymptomatic, ABM = abdominal mass. Codes 1 to 26 are as shown in [Table 1](#cancers-11-01730-t001){ref-type="table"}. a, b, and c, other patients. TC: tumor cells, IC: immune cells.

[^1]: These authors contributed equally to this work.
